46-60 of 773
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Project Oncology®Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Advancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration
Clinician's RoundtableAdvancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration
Chronic Graft-Versus-Host Disease Care: Evolving Therapeutic Strategies
Project Oncology®Chronic Graft-Versus-Host Disease Care: Evolving Therapeutic Strategies
Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
Project Oncology®Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
Project Oncology®Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
Evaluating Axatilimab in Chronic GVHD: How Prior Therapies Impact Outcomes
Project Oncology®Evaluating Axatilimab in Chronic GVHD: How Prior Therapies Impact Outcomes
- advertisement
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Oncology and HematologyAdjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
Oncology and HematologyPatient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
KEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
Oncology and HematologyKEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Oncology and HematologyCohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Amivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
Oncology and HematologyAmivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
Advancing Biomarker Testing Strategies in Upper GI Cancers: From PD-L1 to FGFR2b
Project Oncology®Advancing Biomarker Testing Strategies in Upper GI Cancers: From PD-L1 to FGFR2b
- advertisement
Evaluating Patient and Clinician-Reported Responses to Axatilimab in cGVHD
Project Oncology®Evaluating Patient and Clinician-Reported Responses to Axatilimab in cGVHD
Advancing Precision Medicine in NSCLC: Real-World Impact of the PREDICT Initiative
Project Oncology®Advancing Precision Medicine in NSCLC: Real-World Impact of the PREDICT Initiative
Impacts of Multidisciplinary Tumor Boards and Surgery Integration on NSCLC Survival
Project Oncology®Impacts of Multidisciplinary Tumor Boards and Surgery Integration on NSCLC Survival
